NEUROSTEM®

Phase 1/2a clinical trial completed in Korea62%
62%
Cleared US FDA Phase I/2 IND45%
45%

Treatment of Alzheimer’s Disease

NEUROSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is under development for the treatment of Alzheimer’s Disease. Phase 2a clinical trial has been completed as of December 2019 after successfully completing the Phase 1 clinical trial in Korea.

· Product :NEUROSTEM®
(human Umbilical Cord Blood-derived
Mesenchymal Stem Cells)
· Manufacturer :MEDIPOST Co., Ltd.
· Indication :Treatment of Alzheimer's disease
· Route of Administration :Intra-ventricular administration

Before and after the administration of NEUROSTEM® (animal experiments)

NEUROSTEM® Mechanism of Action video

The accumulation of β-amyloid in the brain, which causes Alzheimer-type dementia, induces learning and memory disorder by damaging the nerve cells. Once NEUROSTEM® is administrated to the patient’s brain with Alzheimer-type dementia, the umbilical cord blood-derived mesenchymal stem cells migrate towards the injury signals within the damaged brain and secrete proteins which stimulate microglia cells. The stimulated microglia cells promote the degradation of β-amyloid by secreting β-amyloid degrading enzymes.

Mechanism of Action for NEUROSTEM®

Research results
· Anti-apoptosis : Kim et al(2010) FEBS Lett. 584(16): 3601-8
· Anti-inflammation : Lee et al(2012) Neurobiol Aging. 33(3): 588-602
· Amyloid-β clearance : Kim et al(2012) Cell Death Differ. 19(4):680-91
· Promotion of neurogenesis : Kim et al(2015) Stem Cells Dev. 24(20): 2378-2390
· Rescue of synaptic dysfunction : Kim et al(2018) Sci Rep. 8(1): 354
· Inhibition of tau hyperphosphorylation & aggregation : To be published

Related News

Menu